State Street SPDR S&P Biotech ETF
XBI
XBI
765 hedge funds and large institutions have $10.2B invested in State Street SPDR S&P Biotech ETF in 2024 Q3 according to their latest regulatory filings, with 87 funds opening new positions, 238 increasing their positions, 270 reducing their positions, and 73 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
1% more funds holding
Funds holding: 758 → 765 (+7)
12% less repeat investments, than reductions
Existing positions increased: 238 | Existing positions reduced: 270
16% less call options, than puts
Call options by funds: $2.8B | Put options by funds: $3.33B
Holders
765
Holding in Top 10
21
Calls
$2.8B
Puts
$3.33B
Top Buyers
| 1 | +$606M | |
| 2 | +$159M | |
| 3 | +$141M | |
| 4 |
D.E. Shaw & Co
New York
|
+$99.1M |
| 5 |
Goldman Sachs
New York
|
+$78M |
Top Sellers
| 1 | -$281M | |
| 2 | -$261M | |
| 3 | -$224M | |
| 4 |
Two Sigma Advisers
New York
|
-$77.1M |
| 5 |
MMFA
Main Management Fund Advisors
San Francisco,
California
|
-$55.5M |